SG10201912964PA - Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease - Google Patents

Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease

Info

Publication number
SG10201912964PA
SG10201912964PA SG10201912964PA SG10201912964PA SG10201912964PA SG 10201912964P A SG10201912964P A SG 10201912964PA SG 10201912964P A SG10201912964P A SG 10201912964PA SG 10201912964P A SG10201912964P A SG 10201912964PA SG 10201912964P A SG10201912964P A SG 10201912964PA
Authority
SG
Singapore
Prior art keywords
tau
alzheimer
diagnosis
protein
disease
Prior art date
Application number
SG10201912964PA
Other languages
English (en)
Inventor
Michal Noväk
Eva Kontsekovä
Branislav Kovácech
Norbert Zilka
Original Assignee
Axon Neuroscience Se
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47216372&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201912964P(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Axon Neuroscience Se filed Critical Axon Neuroscience Se
Publication of SG10201912964PA publication Critical patent/SG10201912964PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
SG10201912964PA 2011-09-19 2012-09-14 Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease SG10201912964PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161536339P 2011-09-19 2011-09-19
US201261653115P 2012-05-30 2012-05-30

Publications (1)

Publication Number Publication Date
SG10201912964PA true SG10201912964PA (en) 2020-02-27

Family

ID=47216372

Family Applications (4)

Application Number Title Priority Date Filing Date
SG10201912964PA SG10201912964PA (en) 2011-09-19 2012-09-14 Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease
SG10201703771WA SG10201703771WA (en) 2011-09-19 2012-09-14 Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease
SG11201400125RA SG11201400125RA (en) 2011-09-19 2012-09-14 Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease
SG10201912955PA SG10201912955PA (en) 2011-09-19 2012-09-14 Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease

Family Applications After (3)

Application Number Title Priority Date Filing Date
SG10201703771WA SG10201703771WA (en) 2011-09-19 2012-09-14 Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease
SG11201400125RA SG11201400125RA (en) 2011-09-19 2012-09-14 Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease
SG10201912955PA SG10201912955PA (en) 2011-09-19 2012-09-14 Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease

Country Status (30)

Country Link
US (5) US9518101B2 (de)
EP (2) EP3275461A1 (de)
JP (7) JP6253583B2 (de)
KR (3) KR20210099167A (de)
CN (3) CN109265543B (de)
AU (3) AU2012311234B2 (de)
BR (1) BR112014006376B1 (de)
CA (1) CA2848346A1 (de)
CL (3) CL2014000679A1 (de)
CY (1) CY1119792T1 (de)
DK (1) DK2758433T3 (de)
ES (1) ES2656442T3 (de)
HK (1) HK1199459A1 (de)
HR (1) HRP20180083T8 (de)
HU (1) HUE036177T2 (de)
IL (4) IL231201B (de)
LT (1) LT2758433T (de)
ME (1) ME03008B (de)
MX (1) MX347505B (de)
MY (1) MY183989A (de)
PL (1) PL2758433T3 (de)
PT (1) PT2758433T (de)
RS (1) RS56852B1 (de)
RU (2) RU2645259C2 (de)
SG (4) SG10201912964PA (de)
SI (1) SI2758433T1 (de)
TR (1) TR201800669T4 (de)
UA (2) UA115657C2 (de)
WO (1) WO2013041962A1 (de)
ZA (1) ZA201401333B (de)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8703137B2 (en) * 2011-01-31 2014-04-22 Intellect Neurosciences Inc. Treatment of tauopathies
CA2877397A1 (en) 2012-07-03 2014-01-09 Washington University Antibodies to tau
MY176838A (en) 2012-08-16 2020-08-24 Ipierian Inc Methods of treating a tauopathy
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
CU24446B1 (es) 2013-03-13 2019-10-04 Prothena Biosciences Ltd Un anticuerpo monoclonal humanizado que se une a tau
BR112016010454A2 (pt) * 2013-11-27 2017-12-05 Ipierian Inc métodos para tratar uma taupatia
US10981953B2 (en) * 2013-12-26 2021-04-20 Toagosei Co, Ltd. Method for promoting expression of calreticulin, and synthetic peptide for use in method for promoting expression of calreticulin
NZ630610A (en) 2014-02-14 2019-05-31 Ipierian Inc Tau peptides, anti-tau antibodies, and methods of use thereof
CA2952745A1 (en) * 2014-06-26 2015-12-30 Janssen Vaccines & Prevention B.V. Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
ZA201608812B (en) 2014-06-26 2019-08-28 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
TW202136296A (zh) 2014-06-27 2021-10-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US10830775B2 (en) 2014-09-30 2020-11-10 Washington University Tau kinetic measurements
BR112017010498A2 (pt) 2014-11-19 2017-12-26 Axon Neuroscience Se anticorpos tau humanizados em doença de alzheimer
TWI669314B (zh) * 2015-02-26 2019-08-21 美國禮來大藥廠 針對ｔａｕ之抗體及其用途
MX2017015464A (es) 2015-06-05 2018-03-28 Genentech Inc Anticuerpos anti-tau y metodos de uso.
KR20180027566A (ko) 2015-07-06 2018-03-14 유씨비 바이오파마 에스피알엘 타우 결합 항체
MA42377A (fr) 2015-07-06 2018-05-16 Ucb Biopharma Sprl Anticorps se liant à tau
JO3711B1 (ar) * 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
GB201518675D0 (en) * 2015-10-21 2015-12-02 Cellcap Technologies Ltd Detection of structural forms of proteins
WO2017189964A2 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
WO2017189959A1 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
CU24538B1 (es) * 2016-05-02 2021-08-06 Prothena Biosciences Ltd Anticuerpos monoclonales que compiten por unirse a tau humano con el anticuerpo 16g7
EP3452508A1 (de) * 2016-05-02 2019-03-13 Prothena Biosciences Limited Antikörper zur erkennung von tau
JP7170316B2 (ja) 2016-05-02 2022-11-14 プロセナ バイオサイエンシーズ リミテッド タウ免疫療法
IL262784B2 (en) 2016-05-18 2023-10-01 Voyager Therapeutics Inc modulatory polynucleotides
KR101997319B1 (ko) 2016-06-21 2019-07-08 전남대학교산학협력단 이형태체 항원인식 항체 생산을 유도하는 플라젤린 백신보조제 기반의 백신의 제조 및 그 응용
JP6949102B2 (ja) 2016-08-09 2021-10-13 イーライ リリー アンド カンパニー 併用療法
FR3058143B1 (fr) * 2016-10-27 2021-03-12 Univ Grenoble Alpes Nanocorps anti-tau
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
JP2020511937A (ja) 2016-12-07 2020-04-23 ジェネンテック， インコーポレイテッド 抗ｔａｕ抗体及び使用方法
KR20230146126A (ko) 2016-12-07 2023-10-18 제넨테크, 인크. 항-타우 항체 및 이의 이용 방법
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11001615B2 (en) 2016-12-21 2021-05-11 Adel Inc. Mutated tau protein fragment and use thereof
CA3053379A1 (en) 2017-02-17 2018-08-23 Denali Therapeutics Inc. Anti-tau antibodies and methods of use thereof
US11028157B2 (en) 2017-03-28 2021-06-08 Janssen Vaccines & Prevention B.V. Binding molecules that specifically bind to tau
WO2018195376A1 (en) * 2017-04-21 2018-10-25 Ohio University Peptide-based inhibitors of mark family proteins
SG11201910066QA (en) 2017-05-02 2019-11-28 Prothena Biosciences Ltd Antibodies recognizing tau
JP7029718B2 (ja) * 2017-07-31 2022-03-04 国立研究開発法人量子科学技術研究開発機構 リン酸化タウタンパク質の測定方法
EP3692536A1 (de) 2017-10-02 2020-08-12 Blackthorn Therapeutics, Inc. Verfahren und systeme zur computergenerierten prädiktiven anwendung von neurobildgebungs- und genexpressions-mapping-daten
MX2020003857A (es) 2017-10-16 2021-01-08 Eisai R&D Man Co Ltd Anticuerpos anti-tau y uso de los mismos.
EA202091012A1 (ru) 2017-10-25 2020-08-27 Янссен Фармасьютикалз, Инк. Композиции фосфорилированных тау-пептидов и их применения
US20200339670A1 (en) * 2017-12-20 2020-10-29 Michael Heneka Novel means and methods for treating neurodegenerative diseases
CN111918875A (zh) 2018-03-11 2020-11-10 库罗什·沙帕桑 构象-特异性的抗神经毒性tau蛋白的抗体
SG11202008098TA (en) * 2018-03-28 2020-10-29 Axon Neuroscience Se Antibody-based methods of detecting and treating alzheimer's disease
RU2679080C1 (ru) * 2018-04-17 2019-02-05 Александр Олегович Морозов Пептид и способ лечения болезни альцгеймера
RU2679059C1 (ru) * 2018-04-17 2019-02-05 Александр Олегович Морозов Пептид и способ лечения болезни альцгеймера
US11085935B2 (en) 2018-05-03 2021-08-10 Washington University Methods of treating based on site-specific tau phosphorylation
SG11202010094TA (en) * 2018-05-03 2020-11-27 Univ Washington Methods of diagnosing and treating based on site-specific tau phosphorylation
KR102585973B1 (ko) 2018-07-03 2023-10-10 에프. 호프만-라 로슈 아게 타우 발현을 조절하기 위한 올리고뉴클레오티드
JP2021530552A (ja) 2018-07-31 2021-11-11 イーライ リリー アンド カンパニー 併用療法
PE20211777A1 (es) * 2018-11-08 2021-09-08 Prothena Biosciences Ltd Anticuerpos que reconocen tau
CN113490505A (zh) * 2018-11-19 2021-10-08 德克萨斯大学系统董事会 用于治疗tau蛋白病的tau肽抗原及与其结合的抗体
KR20210125037A (ko) * 2019-02-08 2021-10-15 프로테나 바이오사이언시즈 리미티드 타우 인식 항체
WO2020180819A1 (en) 2019-03-03 2020-09-10 Prothena Biosciences Limited Antibodies recognizing tau
KR102633666B1 (ko) * 2019-05-31 2024-02-06 일라이 릴리 앤드 캄파니 인간 타우를 표적화하는 화합물 및 방법
GB201909393D0 (en) 2019-06-28 2019-08-14 Gen2 Neuroscience Ltd Tau epitope and binding molecules
AU2020325770B2 (en) * 2019-08-06 2022-08-25 Aprinoia Therapeutics Limited Antibodies that bind to pathological tau species and uses thereof
WO2021030615A1 (en) * 2019-08-13 2021-02-18 Washington University Methods to detect mtbr tau isoforms and use thereof
JPWO2021029181A1 (de) * 2019-08-15 2021-02-18
EP4028040A2 (de) 2019-09-09 2022-07-20 Axon Neuroscience SE Biomarker und behandlungen von morbus alzheimer und milder kognitiver beeinträchtigung
IL270800A (en) * 2019-11-20 2021-05-31 Yeda Res & Dev A method for treating Alzheimer's disease
CN110841059A (zh) * 2019-12-03 2020-02-28 南通大学 老年性痴呆小鼠模型的制备方法
MX2022009607A (es) * 2020-02-05 2022-09-02 Sumitomo Pharma Co Ltd Agente de determinacion y metodo de determinacion de taupatia y enfermedades relacionadas con la demencia.
US20240003918A1 (en) 2020-11-30 2024-01-04 Enigma Biointelligence, Inc. Non-invasive assessment of alzheimer's disease
JP2024506391A (ja) * 2021-02-14 2024-02-13 プロシーナ バイオサイエンシーズ リミテッド タウを認識する抗体の使用方法
TW202246321A (zh) * 2021-02-19 2022-12-01 日商衛材R&D企管股份有限公司 抗pt217 tau抗體
CN113430230A (zh) * 2021-06-24 2021-09-24 南通大学 tau截断体蛋白在诱导tau病理聚集中的应用
WO2023060276A1 (en) * 2021-10-08 2023-04-13 Arbele Limited Compositions and methods for detecting cadherin-17 protein
CN113861441A (zh) * 2021-10-28 2021-12-31 南开大学 一种tau蛋白特异的纳米分子伴侣的制备方法及其在抑制tau聚集中的应用
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
CN116554342A (zh) * 2022-01-29 2023-08-08 元本(珠海横琴)生物科技有限公司 一种融合表达Tau-4R蛋白的大肠杆菌工程菌株
WO2023161526A1 (en) 2022-02-28 2023-08-31 Tridem Bioscience Gmbh & Co Kg A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN
CN117624354A (zh) * 2023-11-30 2024-03-01 无锡傲锐东源生物科技有限公司 一种抗人乙酰化tau281兔单克隆抗体及其应用

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4360019A (en) 1979-02-28 1982-11-23 Andros Incorporated Implantable infusion device
US4424200A (en) 1979-05-14 1984-01-03 Nuc Med Inc. Method for radiolabeling proteins with technetium-99m
US4692147A (en) 1980-04-02 1987-09-08 Medtronic, Inc. Drug administration device
US4479930A (en) 1982-07-26 1984-10-30 Trustees Of The University Of Massachusetts Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US5208036A (en) 1985-01-07 1993-05-04 Syntex (U.S.A.) Inc. N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4725852A (en) 1985-05-09 1988-02-16 Burlington Industries, Inc. Random artificially perturbed liquid apparatus and method
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5811310A (en) * 1986-09-30 1998-09-22 Albert Einstein College Of Medicine Of Yeshiva Univ. The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease
JPH02500329A (ja) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
EP0362371A4 (en) 1988-04-15 1990-10-24 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
ES2118066T3 (es) 1989-10-05 1998-09-16 Optein Inc Sintesis y aislamiento, exentos de celulas, de nuevos genes y polipeptidos.
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
GB9020282D0 (en) 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
DE69233767D1 (de) * 1991-12-06 2009-09-17 Max Planck Gesellschaft Verwendung von Protein-Kinasen zur Diagnose und Behandlung der Alzheimer-Krankheit
WO1994012629A1 (en) 1992-12-02 1994-06-09 Baylor College Of Medicine Episomal vectors for gene therapy
CA2169635C (en) 1993-08-26 2002-11-12 Dennis A. Carson Method, compositions and devices for administration of naked polynucleotides which encode biologically active peptides
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
DE69535901D1 (de) * 1994-10-28 2009-01-29 Max Planck Gesellschaft Proteinkinase npk-110
GB9506197D0 (en) * 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
US5643207A (en) 1995-04-28 1997-07-01 Medtronic, Inc. Implantable techniques for infusing a therapeutic agent with endogenous bodily fluid
US7153510B1 (en) 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
WO1997017614A1 (en) 1995-11-10 1997-05-15 Elan Corporation, Plc Peptides which enhance transport across tissues and methods of identifying and using the same
US5820589A (en) 1996-04-30 1998-10-13 Medtronic, Inc. Implantable non-invasive rate-adjustable pump
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
AU1631700A (en) 1998-11-23 2000-06-13 Idec Pharmaceuticals Corporation Tumor antigen-specific antibody-gp39 chimeric protein constructs
US6198966B1 (en) 1999-02-26 2001-03-06 Medtronic, Inc. Recirculating implantable drug delivery system
JP3383618B2 (ja) 1999-08-18 2003-03-04 松下電器産業株式会社 移動体通信端末装置及び受信強度検出方法
WO2001018546A2 (en) 1999-09-09 2001-03-15 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Screening for inhibitors of 'paired helical filaments'
WO2001018544A1 (en) * 1999-09-09 2001-03-15 Mcgill University Diagnosis, prognosis and treatment of trinucleotide repeat-associated diseases and intranuclear inclusions-associated diseases
US6589746B1 (en) 1999-10-21 2003-07-08 University Of Cincinnati Method of detecting axonally-derived protein tau in patients with traumatic CNS injury
AT500379B8 (de) * 2001-02-02 2009-08-15 Axon Neuroscience Tau-proteine
EP1287831B1 (de) 2001-09-03 2006-11-22 Bio Life Science Forschungs- und Entwicklungsges.m.b.H. Antigen-Mimotope und Vakzine gegen Krebserkrankungen
TWI226905B (en) 2001-10-19 2005-01-21 Bioware Technology Co Ltd Low pressure-accelerated particle gene gun
AU2003246664B2 (en) * 2002-07-12 2007-06-14 Axon Neuroscience Se Transgenic animal expressing Alzheimer's tau protein
JP2006513259A (ja) * 2002-07-24 2006-04-20 イノジェネティックス・ナムローゼ・フェンノートシャップ ベータ−アミロイド生成および／または凝集に関連した疾病の防止、処置および診断
EP1516930A1 (de) 2003-09-16 2005-03-23 Georg-August Universität Göttingen Zelluläres Model der Tauopathien zur "Lead"-Identifikation und zur Entdeckung von Wirkstoffen
MXPA06003886A (es) 2003-10-08 2006-08-11 Ebioscience Reactivos de enlace de inmunoglobulina naturales y metodos de fabricacion y uso de los mismos.
CN1721437A (zh) * 2004-07-13 2006-01-18 中南大学 一种与Tau蛋白相关的多肽抗原及抗体
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
US20070280935A1 (en) 2006-04-07 2007-12-06 Bernd Bohrmann Antibody that recognizes phosphorylated peptides
US8377875B2 (en) * 2007-01-11 2013-02-19 Ramot At Tel-Aviv University Ltd. Therapeutics based on tau/microtubule dynamics
WO2008133208A1 (ja) * 2007-04-20 2008-11-06 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute ペプチド免疫応答増強方法
US20110212075A1 (en) * 2007-06-25 2011-09-01 Siemens Aktiengesellschaft Screening method for polymorphic markers in htra1 gene in neurodegenerative disorders
UA107571C2 (xx) * 2009-04-03 2015-01-26 Фармацевтична композиція
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
JP5917394B2 (ja) 2009-06-10 2016-05-11 ニューヨーク・ユニバーシティ 病理学的タウタンパク質の免疫学的標的化方法
WO2011026031A1 (en) * 2009-08-28 2011-03-03 The Board Of Regents Of The University Of Texas System Antibodies that bind tau oligomers
WO2011053565A2 (en) * 2009-10-29 2011-05-05 Biomedical Sciences Research Centre "Alexander Fleming" Compositions and methods for detecting a tauopathy
DK2496594T3 (en) * 2009-11-06 2018-03-05 The J David Gladstone Inst METHODS AND COMPOSITIONS FOR MODULATING TAU LEVELS
CN102858962A (zh) * 2009-11-19 2013-01-02 索利斯拜欧代因公司 用于增加多肽稳定性和活性的组合物及相关方法
CL2010000019A1 (es) 2010-01-11 2010-06-11 Univ Chile Anticuerpo monoclonal contra el tnf humano y sus fragmentos, secuencias nucleotidicas que lo codifican, vector de expresion y celulas que las contienen, composiciones y kit que comprenden el anticuerpo, uso de los mismos y metodo para su obtencion.

Also Published As

Publication number Publication date
JP6360869B2 (ja) 2018-07-18
IL287794A (en) 2022-01-01
JP2014530597A (ja) 2014-11-20
SI2758433T1 (en) 2018-02-28
HK1199459A1 (en) 2015-07-03
AU2020200624B2 (en) 2021-12-23
US20220010004A1 (en) 2022-01-13
JP2017042172A (ja) 2017-03-02
JP2020072675A (ja) 2020-05-14
US20170260263A1 (en) 2017-09-14
EP3275461A1 (de) 2018-01-31
JP6286590B2 (ja) 2018-02-28
RU2645259C2 (ru) 2018-02-19
HRP20180083T1 (hr) 2018-02-23
KR20200084362A (ko) 2020-07-10
US11098106B2 (en) 2021-08-24
JP6950981B2 (ja) 2021-10-20
AU2012311234B2 (en) 2017-09-28
ES2656442T3 (es) 2018-02-27
CA2848346A1 (en) 2013-03-28
JP6253583B2 (ja) 2017-12-27
IL274440A (en) 2020-06-30
CN104185640B (zh) 2018-07-20
AU2020200624A9 (en) 2021-12-23
SG11201400125RA (en) 2014-03-28
CN109265543B (zh) 2022-04-26
MY183989A (en) 2021-03-17
BR112014006376A2 (pt) 2017-06-13
MX2014003357A (es) 2015-03-20
HRP20180083T8 (hr) 2018-07-27
KR102130439B1 (ko) 2020-07-07
HUE036177T2 (hu) 2018-06-28
KR102285743B1 (ko) 2021-08-06
CN115417916A (zh) 2022-12-02
AU2017272259A1 (en) 2018-01-04
JP2018183160A (ja) 2018-11-22
KR20210099167A (ko) 2021-08-11
CL2015001314A1 (es) 2015-09-21
EP2758433A1 (de) 2014-07-30
RU2014115481A (ru) 2015-10-27
JP2022031631A (ja) 2022-02-22
UA115657C2 (uk) 2017-12-11
BR112014006376B1 (pt) 2021-07-27
IL259775B (en) 2020-05-31
US9518101B2 (en) 2016-12-13
US20170145082A1 (en) 2017-05-25
DK2758433T3 (en) 2018-01-15
IL259775A (en) 2018-07-31
JP2017093470A (ja) 2017-06-01
CN104185640A (zh) 2014-12-03
CL2016000215A1 (es) 2017-08-18
KR20140063853A (ko) 2014-05-27
JP7182316B2 (ja) 2022-12-02
CN109265543A (zh) 2019-01-25
AU2017272259B2 (en) 2019-11-14
MX347505B (es) 2017-04-28
US20150050215A1 (en) 2015-02-19
JP6499345B2 (ja) 2019-04-10
RU2018102103A (ru) 2019-02-21
IL231201A0 (en) 2014-04-30
TR201800669T4 (tr) 2018-03-21
JP2018117631A (ja) 2018-08-02
PL2758433T3 (pl) 2018-06-29
ME03008B (de) 2018-10-20
US20180282401A1 (en) 2018-10-04
SG10201912955PA (en) 2020-02-27
LT2758433T (lt) 2018-02-12
US9845352B2 (en) 2017-12-19
ZA201401333B (en) 2015-09-30
RS56852B1 (sr) 2018-04-30
AU2012311234A1 (en) 2014-05-01
JP6637124B2 (ja) 2020-01-29
CY1119792T1 (el) 2018-06-27
US9828421B2 (en) 2017-11-28
WO2013041962A1 (en) 2013-03-28
EP2758433B1 (de) 2017-10-18
PT2758433T (pt) 2018-01-19
IL231201B (en) 2018-06-28
AU2020200624A1 (en) 2020-02-20
UA123390C2 (uk) 2021-03-31
CL2014000679A1 (es) 2014-11-21
IL274440B (en) 2021-12-01
RU2018102103A3 (de) 2021-05-31
SG10201703771WA (en) 2017-06-29

Similar Documents

Publication Publication Date Title
IL287794A (en) Protein-based therapy and diagnosis of tau-mediated pathology in Alzheimer's disease
IL237369A0 (en) Methods for treating Alzheimer's disease and pharmaceutical compositions thereof
EP2793993A4 (de) Rückgewinnung und verarbeitung von menschlichen in-vivo-embryos
IL232256A0 (en) Purine derivatives and their use in the treatment of diseases
EP2729148A4 (de) Zusammensetzungen und verfahren zur behandlung von symptomen bei patienten mit morbus parkinson
EP3628326C0 (de) Verfahren und materialien zur behandlung von morbus pompe
IL230957B (en) Pharmacy methods and preparations for the treatment of an eye disease in a patient
GB201105137D0 (en) Therapeutic molecules for use in the suppression of Parkinson's disease
IL230441A0 (en) Diagnosis of Alzheimer's disease
EP2568811A4 (de) Behandlung von leichter kognitiver beeinträchtigung und morbus alzheimer
SG11201504447XA (en) Novel pharmaceutical formulations and their use in the treatment of periodontal disease
EP2676665A4 (de) Verwendung von alpha-mangostin bei der herstellung von medikamenten zur behandlung von alzheimer
IL237730B (en) Treatment of mild and moderate Alzheimer's disease
EP2707486A4 (de) Diagnose und behandlung der friedreich-ataxie
PT2603238E (pt) Métodos e composições farmacêuticas para o tratamento de uma doença ocular num indíviduo
IL239078A0 (en) Protein for use in the treatment of eye diseases
ZA201402477B (en) Compounds for use in the treatment of alzheimer's disease
GB201104720D0 (en) Carncin - The use of L-carnosine and cinnamon in the treatment of alzheimer's disease
GB201113718D0 (en) Treatment of Dupuytren's Disease